Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of DZD8586 versus investigator's choice in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
CTR20253196Phase 3Active
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of birelentinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Sep 2025; status: active.
02
Drugs
birelentinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20253196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253196.